GLP1R and cardiovascular disorder: In recent years, two classes of new anti-diabetic agents, SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists shed light on cardiovascular and renal benefits in patients with established or high risks of cardiovascular disease (Dave et al., 2020).